Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for approximately 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages.
The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells. These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. Several risk factors and chromosomal abnormalities have been identified, but the specific cause is not clear. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.
AML has several subtypes; treatment and prognosis varies among subtypes. Five-year survival varies from 15–70%, and relapse rate varies from 33-78%, depending on subtype. AML is treated initially with chemotherapy aimed at inducing a remission; patients may go on to receive additional chemotherapy or a hematopoietic stem cell transplant. Recent research into the genetics of AML has resulted in the availability of tests that can predict which drug or drugs may work best for a particular patient, as well as how long that patient is likely to survive.
This text uses material from Wikipedia
licensed under CC BY-SA
Researchers at Oregon State University and Oregon Health & Science University are working on a treatment that holds great promise for improving the lives of cystic fibrosis patients.
Researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy (BKI) released a study investigating the use of combination checkpoint immunotherapy in the treatment of a ...
Some 50 years since the original "marshmallow test" in which most preschoolers gobbled up one treat immediately rather than wait several minutes to get two, today's youngsters may be able to delay gratification significantly ...
Researchers at the University of Virginia School of Medicine have discovered that microglia, specialized immune cells in the brain, play a key role in clearing dead material after brain injury. The study, which will be published ...
During the past week, the news has brought us difficult images and sounds: Migrant and refugee children huddled in steel cages. Children and parents wailing as they are torn apart by American agents. Detention buses filled ...
A fatty liver disease known as NASH—non-alcoholic steatohepatitis—is the nation's major cause of chronic liver disease, and is projected to become the most common indicator for liver transplants.
Scientists are unveiling how our immune system works – and malfunctions – thanks to an innovative technology that tracks immune cells.
New research by the University of Bristol has found that the microscopic structure of human kidney is different to what was previously known.
Women who spend more time sitting down as they age are at higher risk of becoming frail, a University of Queensland study has found.
Survival times for a highly aggressive type of blood cancer have nearly doubled over the last decade due to the introduction of new targeted drugs, a Yorkshire study has shown.